Overanticoagulation Associated with Combined Use of Antibacterial Drugs and Acenocoumarol or Phenprocoumon Anticoagulants

Summary

Background

Several case reports associated combined use of coumarins and antibacterial drugs with overanticoagulation. Despite the fact that these drugs are frequently prescribed concurrently, there is little quantitative information on the risks of such complications.

Objective

To study which antibacterial drugs are associated with overanticoagulation during therapy with coumarins.

Design

Population-based cohort study in a sample of the Rotterdam Study.

Subjects

All patients who were treated with acenocoumarol or phenprocoumon in the study period from April 1, 1991 through December 31, 1998 and for whom INR data were available.

Methods

Patients were followed until an INR 2: 6.0, the end of their treatment, death or end of the study period. Proportional hazards regression analysis was used to estimate the risk of an INR 2: 6.0 in relation to concomitant use of an oral anticoagulant and antibacterial drugs after adjustment for several potentially confounding factors such as age, gender, hepatic dysfunction, malignancies, and heart failure.

Results

Of the 1124 patients in the cohort, 351 developed an INR 2: 6.0. The incidence rate was 6.9 per 10,000 treatment days. Sulfamethoxazole combined with trimethoprim most strongly increased the risk of overanticoagulation with an adjusted relative risk of 20.1 (95% CI: 10.7-37.9). Stratification showed that the induction period of overanticoagulation varied between different antibacterial drugs.

Conclusion

In this study among outpatients of an anticoagulation clinic using acenocoumarol or phenprocoumon, several antibacterial drugs strongly increased the risk of overanticoagulation. Awareness of these drug interactions and more frequent monitoring of INR values during the initial stages of antibacterial drug therapy are warranted to minimize the risk of bleeding complications.

Keywords

Acenocoumarol - phenprocoumon - anticoagulants

• References

• 1 British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101: 374-87.
• 2 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
• 3 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108: 231S-246S.
• 4 Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of vitamin K antagonists. In: Poller L, Hirsch J. (eds) Oral anticoagulants. London: Arnold; 1996: 9-21.
• 5 Hull R, Hirsh J, Jay R, Carter C, England C, Gent M. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
• 6 Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 01: 1242-5.
• 7 Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
• 8 Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-9.
• 9 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
• 10 Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95: 26S-36S.
• 11 Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med 1971; 285: 487-98.
• 12 Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. 2. N Engl J Med 1971; 285: 547-58.
• 13 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
• 14 van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996; 76: 12-6.
• 15 Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229: 351-5.
• 16 Stockley IH. Drug interactions. 4th ed. London: The pharmaceutical press; 1996
• 17 Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-44.
• 18 Grau E, Real E, Pastor E. Interaction between clarithromycin and oral anticoagulants. Ann Pharmacother 1996; 30: 1495-6.
• 19 Grau E, Fontcuberta J, Felez J. Erythromycin-oral anticoagulants interaction. Arch Intern Med 1986; 146: 1639.
• 20 Soto J, Sacristan JA, Alsar MJ, Fernandez-Viadero C, Verduga R. Probable acenocoumarol-amoxicillin interaction. Acta Haematol 1993; 90: 195-7.
• 21 Jolson HM, Tanner LA, Green L, Grasela TH. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991; 151: 1003-4.
• 22 Hassall C, Feetam CL, Leach RH, Meynell MJ. Potentiation of warfarin by co-trimoxazole. Lancet 1975; ii: 1155.
• 23 Baciewicz AM, Bal BS. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med 2001; 161: 1231.
• 24 Caraco Y, Rubinow A. Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother 1992; 26: 1084-6.
• 25 Bachmann K, Schwartz JI, Forney R, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984; 28: 171-6.
• 26 Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33-41.
• 27 Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989; 08: 210-4.
• 28 Rocci ML, Vlasses PH, Distlerath LM, Gregg MH, Wheeler SC, Zing W. et al. Norfloxacin does not alter warfarin’s disposition or anticoagulant effect. J Clin Pharmacol 1990; 30: 728-32.
• 29 Israel DS, Stotka JL, Rock WL, Polk RE, Rogge MC. Effect of ciprofloxacin administration on warfarin response in adult subjects. Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. 599. Chicago: American Society for Microbiology; 1991: 199.
• 30 Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 1992; 12: 435-9.
• 31 Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103: 422-4.
• 32 Penning-Van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001; 69: 451-7.
• 33 Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 07: 403-22.
• 34 Anonymous. Anatomical Therapeutical Chemical (ATC) Classification Index. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 1993
• 35 Clayton D, Hills M. Time-varying explanatory variables. In: Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993: 307-18.
• 36 Harrison’s Principles of Internal Medicine. 13th ed. Isselbacher, Braunwald, Wilson, Martin, Fauci, Kasper, editors. McGraw-Hill Professional Publishing. 1994
• 37 Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA 1965; 194: 127-9.
• 38 Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82.
• 39 Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
• 40 Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110: 482-90.
• 41 Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90.